Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FDA Approves Noctiva for Frequent Urination

FDA news release; 2017 Mar 3

The FDA has approved Noctiva (desmopressin acetate) nasal spray for frequent urination at night in adults due to overproduction of urine.

Indications: Noctiva is a vasopressin analog indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void.

Dosage/administration: Prime with 5 actuations before initial use if not use for more than 3 days.

  • For patients aged <65 years who are not at increased risk for hyponatremia: Use 1 spray of 1.66 mcg in either nostril nightly approximately 30 minutes before going to bed.
  • For patients ≥65 years or younger patients at risk for hyponatremia: Use 0.83 mcg nightly, which can be increased to one spray of 1.66 mcg after at least 7 days, if needed, provided the serum sodium has remained normal.

Adverse reactions: Common adverse reactions in clinical trials (incidence >2%) included nasal discomfort, nasopharyngitis, nasal congestion, sneezing, hypertension/blood pressure increased, back pain, epistaxis, bronchitis and dizziness.

Citation:

US Food and Drug Administration. FDA approves first treatment for frequent urination at night due to overproduction of urine. FDA Web site. March 3, 2017. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm544877.htm. Accessed March 10, 2017.

This Week's Must Reads

Can Omega-3 Supplement Use Lower CVD Risk?, JAMA Cardiol; ePub 2018 Jan 31; Aung, et al

2018 Adult ACIP Immunization Schedule Released, Ann Intern Med; 2018 Feb 6; Kim, Riley, et al

2018 ACIP Immunization Schedule for Children, MMWR; ePub 2018 Feb 6; Robinson, et al

Weight Management & Remission of T2D in Primary Care, Lancet; 2018 Feb; Lean, Leslie, Barnes, et al

Prior Use of NOACs & Mortality in ICH Patients, JAMA; 2018 Feb 6; Inohara, Xian, Liang, et al

Must Reads in FDA Actions

FDA Approves Steglatro for Adults with T2D, Pfizer news release; 2017 Dec 22

FDA Approves Ozempic for Treatment of T2D, Novo Nordisk news release; 2017 Dec 5

FDA Approves Epinephrine Autoinjector for Infants, Kaléo news release; 2017 Nov 20

FDA Approves Fasenra for Severe Eosinophilic Asthma, AstraZeneca news release; 2017 Nov 14

Shingrix Approved for Prevention of Shingles, GSK news release; 2017 Oct 23